未登录

G

Gil'ad N. Cohen

NYU Grossman School of Medicine

H指数:35

被引数:4,036

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Feasibility of combining high-dose-rate prostate brachytherapy with dose intensification to the MRI dominant lesion followed by real-time adaptive MR-guided pelvic radiotherapy for high-risk prostate cancer

将高剂量率前列腺近距离治疗与对MRI优势病灶进行剂量强化，随后进行实时自适应MR引导盆腔放疗用于高危前列腺癌的可行性

IF1.8

2026-01-010

PRE

High-Dose-Rate Brachytherapy for Vaginal Rhabdomyosarcoma (RMS): Lessons Learned at a Single Institution

高剂量率近距离放射治疗阴道横纹肌肉瘤（RMS）：单一机构经验总结

international journal of radiation oncology biology physics

IF0

2025-03-270

PRE

Modeling absorbed alpha particle dose from diffusing alpha-emitters radiation therapy in changing tissue volumes

在改变组织体积的情况下，对扩散 α 发射器放射治疗吸收的 α粒子剂量进行建模

MEDICAL PHYSICS

IF3.2

2025-01-270

OA

AAPM Task Group 334: A guidance document to using radiotherapy immobilization devices and accessories in an MR environment

MEDICAL PHYSICS

IF3.2

2024-04-220

OAAI

A finite element method for modeling diffusion of alpha-emitting particles in tissue

用于模拟组织中 α 发射粒子扩散的有限元方法

MEDICAL PHYSICS

IF3.2

2023-10-254

PRE

AAPM task group report 303 endorsed by the ABS: MRI implementation in HDR brachytherapy-Considerations from simulation to treatment (vol 49, pg e1023, 2022)

MEDICAL PHYSICS

IF3.2

2022-10-310

OA

Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases (Jul, 10.1007/s11060-022-04101-9, 2022)

JOURNAL OF NEURO-ONCOLOGY

IF3.1

2022-08-230

OA

Salvage resection plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases

JOURNAL OF NEURO-ONCOLOGY

IF3.1

2022-07-2712

OAAI

AAPM task group report 303 endorsed by the ABS: MRI implementation in HDR brachytherapy-Considerations from simulation to treatment

MEDICAL PHYSICS

IF3.2

2022-06-2018

OAAI

Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity

BJU INTERNATIONAL

IF4.4

2021-09-026

OAAI

In vivo imaging characterization of basal cell carcinoma and cutaneous response to high-dose ionizing radiation therapy: A prospective study of reflectance confocal microscopy, dermoscopy, and ultrasonography

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2021-06-0113

OAAI

Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2020-11-018

OAAI

Is there a clinically meaningful change in anatomy during planning of US HDR prostate brachytherapy?

RADIOTHERAPY AND ONCOLOGY

IF5.3

2019-04-011

OAAI

Commissioning of a novel brachytherapy device for diffusive alpha-particle radiation therapy

RADIOTHERAPY AND ONCOLOGY

IF5.3

2019-04-010

OAAI

Comparison of planning US HDR prostate on transversal or longitudinal ultrasound acquisitions

RADIOTHERAPY AND ONCOLOGY

IF5.3

2019-04-010

OAAI

A Phase II Trial of Low Dose Rate Brachytherapy Combined with Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiation Therapy for Clinically Localized, Intermediate Risk Prostate Cancer: A Preliminary Analysis

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2018-11-010

PREAI

Endoluminal High-Dose Rate Brachytherapy for Medically Inoperable Early Stage and Locally Recurrent Esophageal cancer: Implementation of a Novel Applicator and Updated Institutional Experience

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2017-10-010

PREAI

Real-time intraoperative evaluation of implant quality and dose correction during prostate brachytherapy consistently improves target coverage using a novel image fusion and optimization program

PRACTICAL RADIATION ONCOLOGY

IF3.5

2017-09-0112

PREAI

Early clinical results for esophageal brachytherapy using a novel multi-balloon HDR applicator

RADIOTHERAPY AND ONCOLOGY

IF5.3

2017-05-010

OAAI

Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?

RADIOTHERAPY AND ONCOLOGY

IF5.3

2016-10-013

OAAI